Skip to main content

Year: 2024

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commercialization of pz-cel in 2025; Builds momentum with payor discussions and target treatment centers CLEVELAND, Nov. 14, 2024 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the third quarter ended September 30, 2024, and recent corporate updates. “With the acceptance of our Biologics License Application (BLA) resubmission for pz-cel, we are ramping up our commercial readiness efforts, especially with respect to onboarding potential pz-cel treatment sites and continuing discussions with payors,” said Vish Seshadri, Chief Executive Officer of Abeona. Third Quarter and Recent Progress Pz-cel for...

Continue reading

FitLife Brands Announces Third Quarter 2024 Results

Omaha, Nov. 14, 2024 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the third quarter ended September 30, 2024.Highlights for the third quarter ended September 30, 2024 include:Total revenue was $16.0 million, an increase of 15% compared to the third quarter of 2023.   Online sales were $10.8 million, representing 68% of total revenue and an increase of 14% compared to the third quarter of 2023. Gross margin was 43.8% compared to 41.0% during the third quarter of 2023. Net income was $2.1 million compared to $1.7 million during the third quarter of 2023. Basic earnings per share and diluted earnings per share were $0.46 and $0.43, respectively, compared to $0.38...

Continue reading

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal models after one year Alignment with U.S. Food and Drug Administration on development requirements for ATI-1801 NDA Submission HALIFAX, Nova Scotia, Nov. 14, 2024 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the second quarter of its fiscal year 2025, which ended on September 30, 2024. All figures are stated in Canadian dollars unless otherwise stated. “During fiscal year 2025, Appili shareholders voted overwhelmingly...

Continue reading

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalents Targets near-term (1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and various operational efficiency improvements PEMGARDA Fact Sheet updated to properly reflect neutralization activity of PEMGARDA against current circulating variants tested; on track for continued growth now reflective of ongoing commercial optimization Next generation molecule VYD2311 first-in-human clinical trial dosing began in August 2024 with anticipated preliminary data readout late Q4 2024 Management to host conference call today at 8:30AM ETWALTHAM, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted...

Continue reading

Data Center Construction Market to Evolve at a High 7.5% CAGR through 2031 | SkyQuest Technology

Data Center Construction Market size was valued at USD 213.55 billion in 2022 and is poised to grow from USD 229.57 billion in 2023 to USD 409.43 billion by 2031, growing at a CAGR of 7.5% during the forecast period (2024-2031). Westford, USA, Nov. 14, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Data Center Construction market will attain a value of USD 409.43 billion by 2031, with a CAGR of 7.5% over the forecast period (2024-2031). Growing digitization around the world and rising volume of data are slated to promote the construction of new data centers. Rising use of cloud-based technologies and advancements in data center technologies are also expected to bolster data center construction market growth in the future.   Download a detailed overview:  https://www.skyquestt.com/sample-request/data-center-construction-market Browse...

Continue reading

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

The New England Journal of Medicine (NEJM) Letter to the Editor outlines the novel, rapid immunobridging authorization pathway for PEMGARDA and provides an updated correlate of protection curve for monoclonal antibody protection from symptomatic COVID-19 The updated correlate of protection analysis published in the Letter to the Editor indicates the potential for strong protection from symptomatic COVID-19 at titer levels well below doses explored clinically with pemivibart, consistent with recently disclosed CANOPY exploratory efficacy data, and useful for future drug development Company expresses disappointment in NEJM’s publication of a separate Letter to the Editor from a third-party, academic laboratory reflecting outdated, inaccurate virology data produced with “research-grade” “pemivibart” PEMGARDA™ (pemivibart) Fact Sheet...

Continue reading

TransAlta to Acquire Heartland Generation from Energy Capital Partners at a Reduced Price of $542 Million

CALGARY, Alberta, Nov. 14, 2024 (GLOBE NEWSWIRE) — HighlightsTransAlta and ECP have agreed to an $80 million purchase price reduction to reflect two required asset divestitures representing 97 MW (net ownership) Transaction revalued at approximately $542 million, inclusive of the assumption of $232 million of low-cost debt, and subject to a further favourable economic adjustment of approximately $80 million, reflecting the economic benefit of the Heartland business arising since the effective date of the transaction of October 31, 2023, prior to working capital adjustments Heartland portfolio valued at a net price of approximately $270 per kilowatt, with an expected EBITDA multiple1 of approximately 5.4 times Highly accretive to free cash flow, with an attractive cash yield upon closing underpinned by approximately 60% of revenues...

Continue reading

Automotive Wiring Harness Market to Gain USD 67915.16 million by 2031 | SkyQuest Technology

Automotive Wiring Harness Market size was valued at USD 50,266.88 million in 2022 and is poised to grow from USD 51975.95392 million in 2023 to USD 67915.16 million by 2031, growing at a CAGR of 3.4% during the forecast period (2024-2031). Westford, USA, Nov. 14, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Automotive Wiring Harness Market will attain a value of USD 67915.16 Million by 2031, with a CAGR of 3.4% during the forecast period (2024-2031). The growing consensus surrounding driving safety and security is driving up demand for driver-assistance technology like lane departure warning systems, adaptive cruise control, adaptive front lighting, and blind spot recognition. Car makers are also anticipated to fuel market expansion by adhering to strict safety regulations that have been imposed by international authorities....

Continue reading

Goodfood Acquires Controlling Interest in Genuine Tea, A Leading Third-Wave Craft Tea Company

Acquisition Marks Next Stage of Goodfood’s Growth Strategy to Build a Portfolio of Leading Next-Generation Direct-to-Consumer Brands MONTREAL and TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) — Goodfood Market Corp. (“Goodfood” or “the Company”) (TSX: FOOD), a leading Canadian online meal solutions company, is pleased to announce its acquisition of an 81% interest in Genuine Tea Inc. (“Genuine Tea”), a leading Canadian craft tea company. The founding shareholders of Genuine Tea will continue to lead the business and hold the remaining shares of the company, with Goodfood having a right to acquire their shares in the future. The acquisition, financed mainly with Goodfood’s cash reserves, includes future performance-based payment features to the Genuine Tea shareholders. Goodfood is celebrating its 10th anniversary and has developed expertise...

Continue reading

Reed’s Reports Third Quarter 2024 Results and Provides Business Update

Strengthened Liquidity Position with New $10 Million Credit Facility and Assumption of Secured Notes by the Company’s Majority Stockholder Management to Host Conference Call Today at 8:30 a.m. ET NORWALK, Conn., Nov. 14, 2024 (GLOBE NEWSWIRE) — Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, is reporting financial results for the three months ended September 30, 2024. The Company is also providing an update on recent strategic transactions, including the assumption of outstanding secured notes by the Company’s majority stockholder, D&D Source of life Holding LTD (“D&D”). Q3 2024 Financial Highlights (vs. Q3 2023):Net sales were $6.8 million compared to $11.9 million. Gross profit was $1.2 million compared to $4.0 million, with...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.